Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.

Biotechnology

Adverum Biotech

Laurent Fischer

Senior Director, Global Commerical Strategy

Joanna D.

Adam Turpcu

Rabia Gurses Ozden

Romuald Corbau

R. Andrew Ramelmeier

Bill Tan

Linda Rubinstein

Star Seyedkazemi

Dena House

John Rakow

Heikki Jouttijärvi

Kishor Peter Soparkar

Carla Fiankan

The Operations Team at Adverum Biotech is responsible for overseeing and managing various critical functions that ensure the seamless progress and delivery of the company's gene therapy projects. This includes program management, supply chain logistics, quality assurance, quality control in lab operations, and facility management. Their combined efforts support the development and clinical evaluation of ADVM-022, aiming to meet the high standards required for treating serious ocular and rare diseases.

Operations Team

Corporate Affairs

Leadership Team

Scientific Team

Operations Team

About

Team members

Other teams at Adverum Biotech

Corporate Affairs

Leadership Team

Scientific Team